Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation

Eur Respir J. 2019 May 18;53(5):1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May.

Abstract

In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXC

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Beclomethasone / administration & dosage*
  • Bronchodilator Agents / administration & dosage*
  • Drug Combinations
  • Forced Expiratory Volume
  • Formoterol Fumarate / administration & dosage*
  • Glycopyrrolate / administration & dosage*
  • Humans
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Treatment Outcome

Substances

  • Bronchodilator Agents
  • Drug Combinations
  • Beclomethasone
  • Glycopyrrolate
  • Formoterol Fumarate